Skip to main content

Table 1 Comparison of clinical information in the training and validation sets

From: Prediction of neoadjuvant chemotherapy pathological complete response for breast cancer based on radiomics nomogram of intratumoral and derived tissue

Characteristics

Training cohort (n = 93)

Validation cohort (n = 40)

Training VS Validation P value

ALL cohort

Non pCR

pCR

P value

ALL cohort

Non pCR

pCR

P value

Age(year)

51.51 ± 10.42

52.20 ± 10.32

49.56 ± 10.08

0.053

48.15 ± 12.08

48.28 ± 13.37

47.93 ± 10.00

0.931

0.107

Menstrual status

Premenopausal

45 (48.39%)

25 (42.37%)

20 (58.82%)

0.126

26 (65.00%)

14 (56.00%)

12 (80.00%)

0.123

0.078

Postmenopausal

48 (51.61%)

34 (57.63%)

14 (41.14%)

 

14 (35.00%)

11 (44.00%)

3 (20.00%)

  

T stage

T1-2

69 (74.19%)

41 (69.49%)

28(82.35%)

0.172

31 (77.50%)

21 (84.00%)

10 (66.67%)

0.379

0.686

T3-4

24 (25.81%)

18 (30.15%)

6 (17.65%)

 

9 (22.50%)

4 (16.00%)

5 (33.33%)

  

N stage

N1

21 (22.58%)

14 (23.73%)

7 (20.59%)

0.727

14 (35.00%)

6 (24.00%)

8 (53.33%)

0.06

0.136

N0

72 (77.42%)

45 (76.27%)

27 (79.41%)

 

26 (65.00%)

19 (76.00%)

7 (46.67%)

  

BI-RAD stage

4

5 (5.38%)

1 (1.69%)

4 (11.76%)

0.024*

5 (12.50%)

3 (12.00%)

2 (13.33%)

0.9

0.214

5

58 (65.90%)

41 (69.49%)

17 (56.67%)

 

19 (47.50%)

11 (44.00%)

8 (53.33%)

  

6

30(34.09%)

17 (28.81%)

13 (43.33%)

 

16 (40.00%)

11 (44.00%)

5 (33.33%)

  

ER status

Negative

35 (37.63%)

16 (27.12%)

19 (55.88%)

0.006*

18 (45.00%)

6 (24.00%)

12 (80.00%)

0.001*

0.426

Positive

58 (62.37%)

43 (72.88%)

15 (44.12%)

 

22 (55.00%)

19 (76.00%)

3 (20.00%)

  

PR status

Negative

39 (41.94%)

19 (32.20%)

20 (58.82%)

0.012*

19 (47.50%)

7 (28.00%)

12 (80.00%)

0.001*

0.553

Positive

54 (58.06%)

40 (67.80%)

14 (41.18%)

 

21 (52.50%)

18 (72.00%)

3 (20.00%)

  

HER2 status

Negative

55 (59.14%)

44(74.58%)

11(32.35%)

 < 0.001*

24 (60.00%)

18 (72.00%)

6 (40.00%)

0.046*

0.926

Positive

38 (40.86%)

15(25.42%)

23(67.65%)

 

16 (40.00%)

7 (28.00%)

9 (60.00%)

  

Ki-67 status

Negative

27 (29.03%)

23 (38.98%)

4 (11.76%)

0.005*

11 (27.50%)

11 (44.00%)

0 (0.00%)

0.008*

0.858

Positive

66 (70.97%)

36 (61.02%)

30 (88.24%)

 

29 (72.50%)

14 (56.00%)

15 (100.00%)

  

breast cancer subtypes

Luminal A

10 (10.75%)

10 (16.95%)

0 (0.00%)

 < 0.001*

2 (5.00%)

2 (8.00%)

0 (0.00%)

0.004*

0.137

Luminal B

50 (53.76%)

33 (55.93%)

17 (50.00%)

 

20 (50.00%)

17 (68.00%)

3 (20.00%)

  

HER2 positive non luminal

13 (13.98%)

2 (3.39%)

11 (32.35%)

 

12 (30.00%)

4 (16.00%)

8 (53.33%)

  

triple negative

20 (21.51%)

14 (23.73%)

6 (17.65%)

 

6 (15.00%)

2 (8.00%)

4 (26.67%)

  
  1. *indicates statistical significant difference
Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us